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ABSTRACT 
In the industrial sector, the work of the research and development 
departments is related both to the processes performed and to the 
products to be marketed, and it includes everything from the design 
and development of a new product to the redesign or development of 
the process of production. Therefore, response time represents a key 
point in the structure of the company, provided that the response is 
fast and effective. Besides, the quality of the development and design 
is not limited to the benefits of the product. Quality Function 
Deployment (QFD) for Pharmaceutical Products Research and 
Development appears as an important tool that allows us to face the 
design or modification of a product or process according to 
customer’s needs, and to their expectations about the product quality 
requirements. In this work we deal with the development of a plasma 
derived product, on the basis of QFD rules. The application of QFD 
fulfilled the proposed objectives. QFD added simplicity and reliability 
to the production as well security and highly competitive costs to 
both, the product development and the final product itself. QFD was 
supplemented with Good Manufacturing Practices (GMP), and it also 
proved to be highly applicable in the pharmaceutical industry even in 
the case that certification for a quality system is not pursued. 
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1. INTRODUCTION 
1.1. Research and Development in the Pharmaceutical Industry 
 In the industrial sector, the work of the Research and Development 
Departments (R&D Departments) is related to the processes and products to be 
marketed, and it includes everything from the design and development of a new 
product to the redesign or development of the process of production. 
 Pharmaceutical products, like other industrial products, have a life cycle that 
begins with the development of an idea and culminates when the product is 
obsolete, and its redesign, discontinuation, or removal from the market is decided 
(FERRÉ, 1990). 
 One of the objectives of R&D Departments is to extend the mean lifetime of a 
product by improving its design, with parallel development of a substitute for the 
moment when the product is removed from the market (BATES; COLS, 1988). 
 Therefore, response time represents a key point inside the structure of the 
company, provided that the response is fast and effective. Besides, the quality of the 
development and design is not limited to the features of the product but the following 
should also be taken into account (GRAHAM; ENGLUND RANDALL, 1999; RICO, 
1995; NICHOLS, 1994): 
• Simplicity and reliability of the production process 
• Safety and accessibility for maintenance and handling of the product 
• Quality and lack of defects during the product estimated mean lifetime 
 At the same time, it is necessary to work at competitive costs during the 
development process and in obtaining the final product. It is known that cost 
decreases considerably along time as the development of the product progresses 
towards production scale-up, and the production process is optimized in a cycle of 
continuous improvement (SPERY; COLS, 1999; TRHOM, 1990). 
 Thus, another objective of an industrial R&D Department is defined as the 
improvement of products and processes with a view to reducing costs and increasing 
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 net profit margins (TINGSTAD, 1990; GORSKY; NIELSEN, 1992; TINGSTAD; 
1994). 
 In sum, the plans of an industrial R&D Department include two main groups: 
a) Design of new products and processes. 
b) Maintenance and improvement of existing products and processes. 
1.2. QFD for Pharmaceutical Products Research and Development: 
 The central focus of QFD establishes that one of the keys to achieve 
continuous improvement is that internal and external customers get involved as early 
as possible in the process of development of a product (MIZUNO; YOJI, 1994; 
SULLIVAN,1986; AKAO, 1972). 
 Quality Function Deployment is a practice used to design processes in 
response to the needs of the customers, and it translates what customers want into 
what the organization produces. It allows an organization to prioritize customer 
needs, to find innovative responses for those needs, and to improve processes for 
maximum effectiveness. QFD is a practice that leads to process improvements 
which allow an organization to surpass its customers’ expectations 
(SULLIVAN,1986; AKAO, 1972). 
 In the development and improvement of pharmaceutical products, external 
customer needs and requirements are reflected in reliability, effectiveness and 
security of the medication, while internal customers will demand speed, security and 
low costs. (CLARCK; FUJIMOTO, 1991; BECKELL, 1989; SOWREY, 1987; RICO, 
1996; OVIEDO, 2002) 
2. METHODOLOGY 
2.1. QFD for the Research and Development of Human Plasma Derived 
Pharmaceutical Products (Model of Application Developed): 
 In this work we put forward that the development and application of a quality 
system in R&D laboratories result in efficiency and effectiveness gain for the 
manufacture of the product under research. We stated that quality flaws of this 
process are to be found in the planning and programming stages of R&D projects 
and that such flaw include excessive time demanded by the development process as 
well as low attachment to normalized registration systems, among others. 
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  For the implementation of a quality system in R&D groups, we consider that 
QFD can become an appropriate tool that contributes to planning and execution of 
R&D projects. In order to prove this, we carried out the development of a new 
product, applying QFD. 
2.1.1. QFD Methodology Flow:  
 In our work we apply the four basic phases in the methodology of Deployment 
of quality functions, this occurs throughout the process of product development 
(SINGGIH; COLS, 2013; LOWE, 2001; AKAO, 1990; COHEN, 1995). 
 During each phase, we prepare one or more matrices to help plan and 
communicate the critical planning and design information of the selected product and 
process in our case. 
 The applied QFD methodology flow is represented below, where each phase 
or matrix, that we developed represents a specific aspect of the product's 
requirements. The relationships between the elements were evaluated for each 
phase. Only the most important aspects of each phase were implemented in the 
following matrix. 
 Phase 1, Product Planning, incinerating the construction of the house of 
quality with information from the marketing department. Phase 1 documents 
customer requirements, warranty data, competitive opportunities, product 
measurements, competitive product measures and the technical capacity of the 
organization to meet the requirements of each client. 
 Obtaining good customer data in Phase 1 was critical to the success of the 
entire QFD process. 
 Phase 2, product design: this phase included the development work of the 
pharmaceutical product in the Research and Development department. In this phase 
of product design, creativity and innovative ideas related to the product were 
expressed. The concepts of the product were created during this phase and its 
specifications are defined and documented. The clearances that are determined to 
be most important to meet the client's needs were then implemented in the process 
planning during Phase 3. 
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  Phase 3, Planning of processes: process planning is developed following the 
design and supported the assistance of manufacturing engineering. During the 
planning of the process, the production flow diagrams, the critical quantities and the 
process parameters (or reference values) were determined. These are documented 
in the matrix. 
 Phase 4, Process control: Finally, the production planning was determined, 
performance indicators are created to monitor the production process, the 
maintenance schedules and the training of the operators. In addition, in this phase 
the flow of decisions about which process represents the greatest risk was 
determined and fixed and controls are implemented to prevent and avoid failures. 
The controls executed by the quality control department are established. 
2.1.2. Method of Production and Quality System: 
 The method used is the purification of the plasmatic proteins by means of 
alcoholic fractionation, which is known as the Cohn – Oncley Method. (COHN et al., 
1946; CURLING, 1983). 
 The production, quality control and process controls are carried out as 
prescribed by GMP, GLP (OMS, 1994; IRAM-ISO 9000:2000; IRAM-ISO 9001:2000; 
Disposición ANMAT Nº 2819/2004) and other normative regulations (Farmacopea 
Nacional Argentina 7°, 2003, 5° Real Farmacopea Española, 2015). 
2.1.3. Selection of an application project for QFD: 
 Within the Pharmaceutical Industry, the alternatives for the development of 
products and processes can be divided into: 
1. A new product, existing or not in the market, and completely different 
from the range of products existing in the company up to that moment. 
2. A new product, existing or not in the market, and within the range of 
products already existing in the company. 
 In this work, QFD was aimed at the development of a product that is within the 
existing range of products, considering two new alternatives: 
a) Development of a product already existing in the market (generic), 
manufactured using similar processes and procedures as those already 
existing at the industrial plant. 
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 b) Development of new product, already existing in the market, using a process 
of production different from the process currently used at the plant. 
 Our development of QFD was oriented towards an already existing product, 
using production methods installed at the plant. 
 For the Development of QFD, the reengineering and re-launching of a 
completely renewed product which had been discontinued in our laboratory (IgG 
anti-D) was selected. This product exists in the market and its process of production 
does not differ much from the process used for the manufacture of the range of 
products already existing in the company. 
3. DEPLOYMENT THE CASE OF STUDY 
3.1. Description of the Product: 
 Immunoglobulin – Anti-D (Rho) is a biological generic medication. Its 
pharmacological action consists in neutralizing D Antigens (Ag) present in the 
membrane of human red cells (HRC). 
 The medication is made from human plasma coming from healthy donors, 
mostly Rh- women sensitized during pregnancy. In fewer cases, plasma is obtained 
from sensitizations occurred as a result of blood transfusions or programmed and 
controlled immunizations. 
 The use of this medication is mainly directed to prevent the Hemolytic Disease 
of the New Born (HDNB). 
3.2. Need for the Product: 
 It is estimated that 60.000 annual doses of anti-D are needed in the Argentine 
Republic for the prevention of HDNB. According to National Law Nº 23674/89, it is 
obligatory to satisfy that annual requirement, which demands a productive effort in 
accordance with the above mentioned need. 
3.3. Market for the product: 
 This product presents the following market values: 
• In the city of Córdoba, the product annual sale rate reaches about 1000 units, 
which can be potentially increased by 30-40% through a greater supply of 
low-cost, high-quality products. 
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 • In Argentina, 1699 units of the product are sold monthly, distributed in dosage 
forms of 250 and 330 ug of anti-D antibodies/ml. Foreign and private 
laboratories that market imported products occupy 94,97% of this market. 
 Patients can acquire the product, if prescribed by a doctor, in pharmacies that 
buy it from wholesale pharmacy distributors. Public and private hospitals also 
purchase the product, through bidding procedures. 
 The market value of the product is of about  U$S15 per dose of 250 mg/ml, 
and of about U$S 21  per dose of 330 mg/ml. These values correspond to prices of 
the medication in pharmacies. 
3.4. Determination of the Customer Requirements: 
 As a first step, prior to the beginning of the development of QFD, the product 
internal and external customers were defined. 
 The internal customer is someone to whom the R&D department should 
transfer the results of its work, and the external customer is someone that receives 
the final pharmaceutical product form. External customers can be categorized as 
follows: 
a) Primary Customer, who buys the product from the laboratory, and who is 
represented by medical care units, wholesale pharmacy distributors and 
pharmacies. 
b) Secondary Customer, who prescribes the medication, and who is represented 
by the physician. 
c) Tertiary Customer, represented by the patient, for whom the pharmaceutical 
product is prescribed. 
 In a study on customer needs we found that some needs are common to all 
external customers while others are specific of each one of them. 
 Customer needs were determined through interviews and a structured survey 
that allowed us to define the customer satisfaction index in relation to our product 
and to the products of other companies, and also to determine the quality and non-
quality parameters perceived by the customer. The following aspects were also 
determined: causes of quality deficits, internal aspects that could cause bottlenecks 
on the way to the goal of satisfying customer quality requirements, and the internal 
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 perception with regard to the quality of the development project. 
 The objectives of this work are oriented fundamentally to determine an 
administration and quality management methodology applicable to R&D groups. The 
main customer is represented by the sectors that receive findings and developments 
in order to transform them into products. Therefore, QFD is considered to be 
applicable to any research project that provides a result for a determined receiver. 
 Accordingly, during the development of the model we put particular emphasis 
on internal customer requirements. This did not mean to disregard external 
customers who are considered in the global quality development process for every 
R&D project and pharmaceutical product scale-up. When considering internal 
customers, we determined that they are the first receivers of R&D work in an 
industrial laboratory. In the case of university research laboratories, the first receiver 
becomes an external customer. 
 Data were processed statistically in order to determine our priorities and the 
components of the QFD matrix. 
 The most striking internal customers’ requirements and expectations, 
especially those which must be necessarily satisfied, were identified in the analysis. 
Among them, apart from those considered basic, the following were weighted: 
• Greater emphasis on project management. 
• Integration of the development projects into the quality system (do it well from 
the start). 
• Management of development costs (time, results, equipment, etc.). 
• Efficiency in project management, with an improved planning/results 
relationship. 
• Greater interaction with internal customers, such as Quality Control and 
Production. 
• Greater speed in development transfer for development scale-up. 
• Transfer in accord with production manuals, standard operational procedures 
and work manuals at the moment of scaling up. 
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 • Greater participation in the stage of final adjustment of the development 
process. 
• Decrease in the percentage of post transfer and post scale-up adjustments. 
 In order to determine which of the above mentioned items were essential, they 
were evaluated through a Pareto diagram, which showed the results displayed in 
Table 1, Figure 1 and Figure 2. 
Table 1: Internal customer requirements values 
Requirements Order Value % Accumulated %  
Project Management 1 36 31.30 31.30 
% Post Transfer Adjust  2 27 23.48 54.78 
Transfer Time 3 22 19.13 73.91 
R&D Costs 4 20 17.39 91.30 
Interaction with other Depts. 5 7 6.09 97.39 
SOPs and Manuals 6 3 2.61 100 
TOTAL  115 100  
 
 
Figure 1: Weighted Internal Customer Requirements 
 
Requiremets / Needs 
Internal Customer 
32% 
23% 19% 
17% 
6% 3% 
Project Management 
Post  Ajust  
Transfer % 
Transfer time 
R&D Costs 
 Interaction with other 
Departments 
 SOPs and Manuals 
 
Figure 2: Percentage Distribution of Internal Customer Requirements 
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  Regarding the external customer, it was observed that the most important 
requirements were reflected in the need for products with adequate market 
availability and supply, at low cost, and with more potent formulations and stability. 
Other needs were related to the intravenous form of the product and to the possibility 
of adjusting the doses according to the degree of sensitization of the patient. 
 The results of the Pareto diagram, designed to show the degree of importance 
of each one of these requirements, can be seen in table 2, Figure 3 and Figure 4. 
Table 2: External customer requirements values 
Requirement/Need Order Value % Accumulated % 
Market supply 1 411 35.55 31.30 
Low Costs 2 221 19.12 54.67 
More Potency 3 202 17.47 72.15 
Expiration Date 4 202 17.47 89.62 
Intravenous form 5 80 6.92 96.54 
Multi Doses 6 40 3.46 100 
TOTAL  1156 100.00  
 
 
Figure 3.Weighted External Customer Requirements 
 
Requiriments / Needs 
External Customer 
37% 
19% 17% 
17% 
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Multi Doses 
 
Figure 4: Percentage Distributions of External Customer Requirements 
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  A spiderweb interrelationship digraph (Figure 5) was used in order to identify 
the points in common between both results. It was observed that the main interaction 
points were related to the cost and time of development, that is, to the planning 
process and to good project management. 
 This analysis facilitated the stratification and selection of needs and it allowed 
building the QFD matrixes. Figure 4 presents a practical scheme of the QFD applied. 
31,30
23,48
19,13
17,39
6,09
2,61
35,55
19,12
17,47
17,47
6,92
3,46
0,00
10,00
20,00
30,00
40,00
40
30
205
2,5
Internal
Customer
Requireme
External
Customer
Requireme
 
Figure 5: Internal vs. External Customer Interrelationship Diagraph (spider web) 
 Once the matrixes were completed, we advanced in the development of the 
project, the control parameters were determined for each stage, and the project 
improvement indicators were defined. During the realization of the project, the 
inspection points of the process were defined, the techniques and control trials used 
were optimized and validated, and the critical parameters of the production process 
were adjusted. 
 After de product development was finished, the standard operative 
procedures (SOP) involved in the production process of the new product, its 
manufacturing manual and the engineering design process were written, for the 
subsequent scale-up process. 
4. RESULTS AND EVALUATION OF THE APPLICATION OF QFD IN A 
PROCESS OF RESEARCH AND DEVELOPMENT 
 A traditional point of view considers a product R&D from the market and 
marketing perspectives; however, it should be taken into account that the 
development of a new medical product requires a minimum of five years from the 
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 beginning of the development until the product is obtained. With the application of 
QFD we plan to reduce that time and achieve a sustained increase in quality. 
 In our case, one of the most important customer requirements was related to 
efficient and effective R&D project planning and to appropriate decision-making for 
the project evaluation. 
 Within that framework, the results obtained are ordered under the following 
titles: 
a) Project Planning 
b) Evaluation of the QFD results 
4.1. Project Planning: 
 For efficient project planning, the application of five governing points was 
determined, whose execution represents a considerable improvement in the quality 
of the development of a new medicine. 
a) The R&D Manager, the Product Development Chief, or the Researcher must 
carry out the project planning process as if acting on behalf of the Company 
Direction, that is to say, they must assume the management role from a global 
perspective, as from the moment the new idea is conceived. 
b) The project planning process should attain a balance between the conflicting 
interests and requirements of a company on the path of quality, and some 
conservative management practices applied when the production, marketing, 
sales, finances and quality areas are involved. 
c) The planning process should contain the definition of pre-requirements for the 
development process and the definition of the product to be obtained from the 
said process. 
d) The project planning process should generate the creation of a New Project 
Committee, composed by the following members and areas of the company: 
Researchers, Plant Managers, Technical Direction, Marketing, Quality, and 
Executive Directors. The creation of the committee should allow a global 
vision of external and fundamentally of internal customer requirements. 
 
 
 
[http://creativecommons.org/licenses/by/3.0/us/] 
Licensed under a Creative Commons Attribution 3.0 United States License 
 
852 
INDEPENDENT JOURNAL OF MANAGEMENT & PRODUCTION (IJM&P) 
http://www.ijmp.jor.br v. 9, n. 3, July - September 2018 
ISSN: 2236-269X 
DOI: 10.14807/ijmp.v9i3.751 
 
 e) The project planning process should generate awareness that beginning and 
defining a project for a new medication or for a new production process 
represents only one instant in the planning process as a whole. During the 
project planning process, the project director should maintain an innovative 
vision of customer requirements. Besides, the director must ensure that all the 
contents related to quality as well as the commitment of all the members of 
the organization are taken into account for the development and successful 
realization of the project. 
 In this part of the work we will not go into detail on how and when the above 
mentioned points should be applied. Instead, we will simply analyze how the project 
planning process and the quality function deployment influenced the development of 
the project. In the chapter referred to project planning, a detailed explanation of how 
to execute the planning process is provided. Planning involved an analysis of the 
environment and of strengths and weaknesses of the project (Figure 6). 
Subsequently, a strategic action plan was determined for the development of the 
project. 
 
Figure 6: Scheme of the SWTO Analysis for the R&D Project 
 The project was then structured in five stages that in turn are composed by a 
group of activities representing the development of the project. The finalization of 
each stage signals a point of control and of decision making where the continuity or 
the end of the project is decided. 
 Stages 1, 2 and 3 are the lengthiest ones and they represent the greatest 
investment in the development of the project. It was decided that Stage 1, Evaluation 
and Selection of the Project, would last longer than in previous projects. This 
constituted an important aspect for making decisions at the beginning of and during 
the research and development project (Figure 7). 
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Figure 7: Evaluation of multi-project implications along the three-year development 
study: case study project (*), other simultaneous projects (*). 
 Another aspect considered was the development, quality and investment 
costs, which were reduced by 18% in relation to the initial projection and by 30% as 
compared with previous projects (Figure 8). 
 
Figure 8: Project Costs vs. Project Investment, (---) Planned Costs, (---) Actual Costs 
(QFD-based Project) and Costs of other Project (---). 
 A staggered schedule of activities as well as the participation and involvement 
of different departments of the company allowed interaction with existing projects 
and optimization of the employment of resources through the evaluation of multi-
project implications (Figure 7) (ALLEN, 1994).  
 This allowed the company to generate an interactive planning process and 
almost constant revision of existing projects so as to avoid and eliminate limitations 
that might otherwise stay out of control. 
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  In this way, the developers and personnel in charge of other projects did not 
have to wait until their respective projects were finished in order to become involved 
in the planning of a new one. Otherwise, the result would have been insufficient 
project planning. 
 Planning implied taking into account assumptions about needs, such as the 
following: 
• Volumes: They refer to the capacity of the plant to process and to obtain the 
new product, the degree of automation of the process, the materials that can 
be used in product development and design and for the corresponding 
process, the design of new components, and the cost of application of the 
technologies adopted. 
• This practice was beneficial from the perspective of team work, as all the 
departments involved in the project were consulted for consensus decision 
making in order to advance, obtain results, and fulfill the objectives. The result 
was that experimental development planning work was carried out on the 
basis of realistic volume estimations and that the work was adjusted to the 
capacity and infrastructure of the company. This impacted significantly on the 
investment and on the reduction of the development costs (Figure 8). 
• Another planning aspect involved legal aspects: all legislation related to the 
project was gathered and it was specially taken into account during the 
evaluation, approval and start-up stages. This work facilitated the task of 
stage five, related to the final development of the complete Quality Assurance 
and Regulatory Documentation required for the official registration of the new 
medicinal product developed. 
 On the basis of the organization of specific activities for each department 
participating in the project, parallel lines of work were generated so that the 
responsibility for the execution of the project did not lie entirely on the Research and 
Development Department (Figure 7). 
 This implied that different aspects of the development process progressed 
simultaneously: while experimental tests were conducted, Plant Engineering solved 
the requirements for equipment and infrastructure, or Quality Management advanced 
in the preparation of the necessary documentation. This allowed the company to 
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 reduce development time by 35%, (we had said that a pharmaceutical development 
requires at least five years to be completed), with the corresponding reduction in 
arising expenses (Figure 9). 
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Figure 9: R&D Project Deployment Time 
 Planning and the employment of quality tools generated joint tasks, 
consensus decision making, and integration of teams generally acting in a stratified 
manner. The most important result is not -as it could be presupposed- economic 
profit, but the cultural and educational transformation achieved by using this method 
of working. 
 Early knowledge of internal and external customer requirements allowed the 
developers of the project to value needs and demands, to determine quality 
standards, and to make the necessary changes in the original plans of the project in 
order to respond to customer requirements according to actual transfer and 
production possibilities. In other words, in the pharmaceutical industry a new idea is 
actually good only if it can be materialized into a quality product made at low cost 
production. 
 One of the planning keys was to translate the requirements into the product 
specifications, in an economical way. QFD represents a good tool that allows the 
company to ensure, in a structured way, that what began as a customer requirement 
is considered all along the development process and is transferred to production in 
the most economical way possible, always assuring the maximum quality standard. 
4.2. Evaluation of the Results of the QFD: 
 As we said before, QFD means transferring the customer opinion to the 
product. We also assert that the essence of planning a new project is to define the 
orientation towards the customer so that researchers and technologists can 
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 transform that orientation into a technical tool for quality and high profitability 
production. 
 In our hypothesis we put forward that it was possible to achieve that 
requirement by using QFD for the development of a medicine. 
 Planning work brought about an action plan that is summarized in the 
following five points: 
• New QFD Development 
• Determination and elimination of bottlenecks 
• Development of the new product 
• Putting the process under control 
• Production and sales 
 Quality Function Deployment was completed as explained before. In order to 
evaluate the results and to confirm the validity of the hypotheses formulated, the 
following were defined as quality indicators: 
(A) Time of realization of the development 
(B) Percentage of delays in the development 
(C) Investment 
(D) Costs 
(E) Percentage of reprocess and secondary developments subsequent to transfer 
(F) On the basis of market trends, compliance with quality requirements 
(G) Positioning in the market 
(H) Competitiveness. 
(I) Number of scientific publications derived from the development of the product 
 In spite of the forecasts, in the course of the experimental development there 
appeared some bottlenecks that represented a constraint for the execution of the 
proposed objectives. Those restrictions were often related to: 
a) Delays in the provision of equipment, reagents and drugs coming from abroad 
which was due to the economic situation and bureaucratic problems of the 
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 country, related to customs procedures that exceeded any previous planning. 
Besides, insufficient equipment had to be shared among other simultaneous 
projects (situation that had been taken into account in the multiproject 
analysis) as well as with other sectors such as Quality Control. 
b) Excessive wear and fatigue in some equipment, which caused delays for 
repairs and corrective maintenance. 
c) Modification of experiments and reagents as a result of experimental 
development, which originated the need to buy new drugs and equipment. 
 It is normal that experimental and research work result in changes in the 
original plans leading to the need to find new and different ways to achieve the 
objectives, which may give origin to new needs with the consequent delays in the 
predetermined terms. It is normal and preferable for this to happen at this stage of 
the development and not at later stages; in fact, this type of modifications makes the 
measures taken at the moment of a new product transfer and scale-up more reliable. 
 Regarding bottlenecks, the first task was to determine their causes in order to 
eliminate them. In some cases, such as those related to experimental work, the 
causes were not eliminated completely since they were inherent in the research and 
product development work. However, a solution was sought for those causes related 
to equipment maintenance and repair, which consisted in an equipment validation 
program and a preventive maintenance plan.  
 In order to avoid stopping the development of the project and generating 
major delays, the decision was made to carry on with the project, and continue 
dealing with the constraints until their causes could be eliminated. For that purpose, 
in some cases drug and reagent stocks and work shifts were rearranged in 
accordance with the activities plan for each project in course. 
 The results allowed the evaluation of the behavior of the quality indicators 
considering two aspects, related to: 
I. Management and Internal Customer Requirements 
II. The Product, Market Positioning and External Customer Requirements 
 Time of Development: The development of products belonging to the same 
family took between 6 and 7 years to be completed, while with the application of 
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 QFD that time decreased to 4 years, which meant 35% less time. Figure 7 shows the 
time required for the development of a process in which QFD was not applied, 
compared with our process, in which QFD was applied.  
 The most important difference is centered on stage 1, and during the planning 
process time. This allowed the company to execute more efficiently the research and 
development stages and also to reduce time in the final stages of the project. 
 Delays: Although with the application of QFD and process planning it was not 
possible to avoid delays completely, their final incidence on the transfer from the 
product development to production scale decreased. Figure 10 details the 
corresponding reduction percentages. 
  
Figure10: R&D Project Delays 
 Development Investment: With the use of QFD we considerably modified the 
development investment model, as we distributed the budget so that the greatest 
portion was assigned to the initial stages. The decrease in expenditure or non-quality 
costs allowed the company to make a total investment that resulted slightly smaller 
than the estimate, thus improving the project profit (table 3). 
Table 3: R&D Investment and Costs (U$D) 
 
Stage 
R&D Investments vs. Costs  
QFD-based Project Non QFD-based Project 
Investment 
$ 
Total Cost 
$ 
Non-Q cost$ Planned Inv. 
$ 
Total Cost 
$ 
Non Q cost 
$ 
1 30000 45000 260 15000 10000 2650 
2 60000 50000 4100 45000 47000 2350 
3 75000 65000 2350 60000 70000 7000 
4 75000 50000 2040 75000 60000 6000 
5 30000 30000 3200 60000 20000 10000 
6 30000 5000 300 45000 113000 84000 
Total 300000 245000 12250 300000 320000 112000 
% 100 18 5 100 107 23 
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  Assigning more funds to the initial stages allowed the company to carry out 
trials and the necessary corrections during the experimental development, adjusting 
the process so that in the transfer and scale-up stages, the investment gradually 
decreased. This trend becomes apparent when the new project is compared with 
previous ones, since in general, in those developments the investment would 
become higher at the final moments, often as the result of an increase in costs 
derived from corrections and secondary developments subsequent to transfer of 
development (Figure 11). 
 
Figure 11: Investment Planning 
 Multi-project planning, team work, efficiency in the use of equipment and 
resources, and continuous improvement from the “do it well from the start” 
perspective generated savings in relation to the initial investment forecast. QFD 
allowed the company to work under quality standards that avoided deviations from 
the initial objective and unnecessary experimental developments parallel to the main 
project, which generally respond to matters that draw the attention of the researcher. 
 Development Costs: An efficient project shows a rise in costs during the initial 
stages, and a reduction to a minimum amount towards the end of the final stages. 
In projects with inefficient planning and poorly defined quality criteria the cost 
curve was shaped inversely in relation to our proposed project (Figure 6). It showed 
a rising trend even when the development product had already been totally 
transferred to production -let us remember reprocess and secondary development 
necessary for the correction of errors or to lack of foresight. All these costs often 
responded to incorrect project planning and to non-quality (Figure 12). 
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Figure 12: Planned investment vs. project and Non Quality costs. 
 As of QFD application, efforts were aimed at improving the quality of the 
development process and of the project administration and management. Besides, 
more attention was paid to the customer's voice, and the development and 
experimental works were adjusted to an action plan with finite life and exposed to 
continuous evaluations for the purpose of making it more efficient (Figure 13).  
 
Figure 13. Cost Distribution vs. Project  Stages. 
 This group of actions produces a decrease in the costs, especially on those 
related to non-quality, and a distribution of expenditure that is close to an ideal 
distribution (Figure 13). 
 Reprocess and Secondary Developments subsequent to Transfer: We put 
forward that one of the non-quality indicators for product development is represented 
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 by the number of corrections made on a complete development project. In fact, this 
situation illustrates the consequences of lack of planning, managerial deficiencies 
and inadequate decision making during the course of the project. 
 We often believe that these corrections are related to technical aspects, but 
they actually involve all the aspects of the project. Sometimes, poor advice on legal 
aspects may cause countermarches that delay the definitive launching of the new 
product. In the case developed a decrease in the percentage of changes was 
attained because all the necessary corrections were made during the experimental 
stages so that only final adjustments remained for the transfer and production stages 
(Figure 14). 
 
Figure 14. Changes in the project 
 Quality Requirements: QFD development allowed us to comply with quality 
requirements and to respond to quality demands. Besides, the market trend for those 
requirements considered most important was determined through a projection 
covering 3 to 5 years as from the end of the development. Figure 15 shows the 
product potency trend and the position occupied by the product developed.  
 The project allows us to obtain two different potencies of 330 and 250 ug 
which respond to customer needs, and to compete within the market trend for the 
coming years. The process of constant feedback and continuous improvement 
should provide a more potent product by the end of the abovementioned period. For 
that purpose, a new project is launched, involving new production technologies. 
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Figure 15: Required Quality: Potency in ug 
 In relation to potency, the solution volume presented in vials shows a 
tendency to decrease (Figure 16) as a purer product with greater specific potency is 
produced. Other aspects that responded to customer requirements were related to 
the information appearing on the package, packaging type, final price of the product 
and its availability in the market.  
 
Figure 16: Required Quality: Volume per vial. 
 Figure 17 (A-B) shows how the said improvements affected the position of the 
product in the market. Positioning in the Market: Figure 17 shows the product 
behavior in the market, in terms of quality required by the customer.  
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Figure17 (A):  Product behavior in the market in terms of the quality required by the 
customer.  Laboratory (H) vs. other Laboratories (B, P, G). Before QFD 
 Prior to QFD development, a projection was made starting from the product 
behavior before it was redesigned. The improvement observed in the new product 
becomes more evident in the growth of the market portion that it occupies and in its 
quality/price relationship. 
 
Figure17 (B): Product behavior in the market in terms of the quality required  by the 
customer.  Laboratory (H) vs. other Laboratories (B, P, G). After QFD 
 Competitive evolution of the product: As from the application of QFD to the 
development of the product, the evolution of the product in relation to competitors’ 
products showed continuous improvement. Figure 18 shows the behavior of the 
various quality requirements expressing the external customer needs. 
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Figure18: Position in the market. QFD-based product (Lab. H) vs. other Laboratories 
products (B, P, G). 
5. FINAL CONSIDERATIONS:  
 In every research and development process, the possibility of making good 
decisions is lower at the initial stages of the project, hence the importance of quality 
planning. Undoubtedly, good planning represents assurance of the product 
development quality from the beginning itself, and reduction in non-quality costs 
caused by making wrong decisions (CHENG; DE MELO FILHO, 2010; PRAMOD, 
2018). 
 This idea implies the decision of investing more and better resources in the 
initial stages of the project, and avoiding expensive correction cycles after the 
development is finished. 
 If something that is relatively simple has not yet been appropriately dealt with 
within the realm of a research and development group, it is due to an incorrect vision 
of multifunction work, which requires correct project planning. 
 We can assert that QFD is an appropriate tool for the management of a 
development project since it allowed us to establish the necessary links between 
product excellence, internal and external customer needs, and the opportunities 
existing in a competitive market.  
 QFD created the need to establish planning mechanisms for research and 
development projects in the short, medium and long term, in order to avoid 
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 subjective evaluations and decisions made by people wrongly believing to be project 
management experts. 
 QFD requires working methods that led to reductions in interdivisional clashes 
and jealousy as well as in conflicts of power between researchers, product 
developers, and control, production and marketing technicians. This allowed the 
execution of projects with collaborative participation of personnel of the most diverse 
areas and the consequent simplification of planning and control tasks. Besides, QFD 
made it possible for the personnel to share the responsibilities arising from the 
project. 
 The opinion, suppositions or subjective desires of researchers were not 
mistaken for customer requirements; thus, the satisfaction of customer needs was 
attained and expressed in the final product. Besides, QFD proved to be applicable to 
any area of the organization or to any of its processes, culminating in the design of 
products in accord with customer requirements. 
 Once the application QFD is finished, it becomes a knowledge tool that may 
be used for later developments of components or systems specified for other 
products. This avoids reinventing the wheel, so that the transfer of knowledge from 
project to project is safeguarded and time is saved. 
 The application of QFD required training and discipline, which helps to attain a 
cultural change in the research and development process even if such application is 
not easy when dealing with completely new and creative ideas. In fact, in these 
cases the most difficult task will be to determine customer requirements (STEFAN 
SCHURR; ARCIDIACONO, 2011). 
 We put forward that QFD contributes benefits to the research and 
development process, mainly for industrial research teams, since it allows them to 
improve competitiveness along with quality and productivity. The development 
process acquires the characteristics of orientation towards the customer, efficiency in 
time-management, orientation to team work, and permanent documentation of the 
process (YACUZZI; MARTÍN, 2003; GORIYA, 2016). 
 An organization with total quality management is an organization oriented 
towards the customer. QFD requires gathering customer input and feedback, 
information that is translated into a group of customer specific requirements. The 
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 performances of the organization and of competitor organizations in relation to 
requirements are carefully studied. This allows the organization to compare itself 
with competitors with respect to customer needs satisfaction 
(VONDEREMBSE; RAGHUNATHAN, 1997). 
 QFD reduces the time of development because it is centered on specific and 
clearly identified customer requirements. As a result, there is no time waste in 
developing features that have little or null value for the customer. 
 QFD is an approach oriented to team work. All decisions are based on 
consensus and they include thorough brainstorming and discussion. Since all the 
actions to be taken are identified as parts of the process, individuals can visualize 
their position within the organization, which fosters team work. 
 QFD emphasizes the documentation aspect. One of the products of the QFD 
process is a comprehensive and complete document which gathers all relevant data 
about all processes and their performance in relation to customer requirements. That 
document is constantly updated as new information is known and obsolete 
information is discarded. Updated information on customer requirements and on 
internal processes is particularly useful when problems arise. 
 Finally we can assert that with QFD application the proposed objectives were 
fulfilled. QFD added simplicity and reliability to the production, and security and 
highly competitive costs not only to the product development but also to the final 
product. QFD was supplemented with GMP and it proved to be highly applicable in 
the pharmaceutical industry even in the case that certification for a quality system is 
not pursued. 
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